BSCI
Guggenheim BulletShares 2018 Corporate Bond ETF
stock NYSE

I haven’t seen anyone mention the key concern that caused the sector to sell off, GLP-1’s.
There is some concern that minimally invasive tech forecasted demand for chronic conditions could be negatively impacted due to a reduction in the obese population.
BSC was particularly negatively impacted due to Watchman having both a competitor (Abbott) come into the space and results from a clinical trial comparing it to blood thinners that wasn’t as enticing of data as expected.
Last is their PFA tech (Fara) which is the hottest category in MedTech is losing market share to competition.
In summary BSCI was valued at a premium by Wallstreet because they had the only real offering in two high-growth categories (LAAC - Watchman, PFA - Fara), and since that point, the market share, growth rate, and TAM are in question.
ICE, RDN, and IVL technologies are the keys to watch moving forward.

I haven’t seen anyone mention the key concern that caused the sector to sell off, GLP-1’s.
There is some concern that minimally invasive tech forecasted demand for chronic conditions could be negatively impacted due to a reduction in the obese population.
BSC was particularly negatively impacted due to Watchman having both a competitor (Abbott) come into the space and results from a clinical trial comparing it to blood thinners that wasn’t as enticing of data as expected.
Last is their PFA tech (Fara) which is the hottest category in MedTech is losing market share to competition.
In summary BSCI was valued at a premium by Wallstreet because they had the only real offering in two high-growth categories (LAAC - Watchman, PFA - Fara), and since that point, the market share, growth rate, and TAM are in question.
ICE, RDN, and IVL technologies are the keys to watch moving forward.